Melina Dritsaki1, Felix Achana2, James Mason2, Stavros Petrou2. 1. Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, UK. melina.dritsaki@ndorms.ox.ac.uk. 2. Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, CV8 7AL, UK.
Abstract
BACKGROUND: Trial-based cost-utility analyses require health-related quality of life data that generate utility values in order to express health outcomes in terms of quality-adjusted life years (QALYs). Assessments of baseline health-related quality of life are problematic where trial participants are incapacitated or critically ill at the time of randomisation. This review aims to identify and critique methods for handling non-availability of baseline health-related quality of life data in trial-based cost-utility analyses within emergency and critical illness settings. METHODS: A systematic literature review was conducted, following PRISMA guidelines, to identify trial-based cost-utility analyses of interventions within emergency and critical care settings. Databases searched included the National Institute for Health Research (NIHR) Journals Library (1991-July 2016), Cochrane Library (all years); National Health Service (NHS) Economic Evaluation Database (all years) and Ovid MEDLINE/Embase (without time restriction). Strategies employed to handle non-availability of baseline health-related quality of life data in final QALY estimations were identified and critiqued. RESULTS: A total of 4224 published reports were screened, 19 of which met the study inclusion criteria (mean trial size 1670): 14 (74 %) from the UK, four (21%) from other European countries and one (5%) from India. Twelve studies (63%) were based in emergency departments and seven (37%) in intensive care units. Only one study was able to elicit patient-reported health-related quality of life at baseline. To overcome the lack of baseline data when estimating QALYs, eight studies (42%) assigned a fixed utility weight corresponding to either death, an unconscious health state or a country-specific norm to patients at baseline, four (21%) ignored baseline utilities, three (16%) applied values from another study, one (5%) generated utility values via retrospective recall and one (5%) elicited utilities from experts. A preliminary exploration of these methods shows that incremental QALY estimation is unlikely to be biased if balanced trial allocation is achieved and subsequent collection of health-related quality of life data occurs at the earliest possible opportunity following commencement of treatment, followed by an adequate number of follow-up assessments. CONCLUSION: Trial-based cost-utility analyses within emergency and critical illness settings have applied different methods for QALY estimation, employing disparate assumptions about the health-related quality of life of patients at baseline. Where baseline measurement is not practical, measurement at the earliest opportunity following commencement of treatment should minimise bias in QALY estimation.
BACKGROUND: Trial-based cost-utility analyses require health-related quality of life data that generate utility values in order to express health outcomes in terms of quality-adjusted life years (QALYs). Assessments of baseline health-related quality of life are problematic where trial participants are incapacitated or critically ill at the time of randomisation. This review aims to identify and critique methods for handling non-availability of baseline health-related quality of life data in trial-based cost-utility analyses within emergency and critical illness settings. METHODS: A systematic literature review was conducted, following PRISMA guidelines, to identify trial-based cost-utility analyses of interventions within emergency and critical care settings. Databases searched included the National Institute for Health Research (NIHR) Journals Library (1991-July 2016), Cochrane Library (all years); National Health Service (NHS) Economic Evaluation Database (all years) and Ovid MEDLINE/Embase (without time restriction). Strategies employed to handle non-availability of baseline health-related quality of life data in final QALY estimations were identified and critiqued. RESULTS: A total of 4224 published reports were screened, 19 of which met the study inclusion criteria (mean trial size 1670): 14 (74 %) from the UK, four (21%) from other European countries and one (5%) from India. Twelve studies (63%) were based in emergency departments and seven (37%) in intensive care units. Only one study was able to elicit patient-reported health-related quality of life at baseline. To overcome the lack of baseline data when estimating QALYs, eight studies (42%) assigned a fixed utility weight corresponding to either death, an unconscious health state or a country-specific norm to patients at baseline, four (21%) ignored baseline utilities, three (16%) applied values from another study, one (5%) generated utility values via retrospective recall and one (5%) elicited utilities from experts. A preliminary exploration of these methods shows that incremental QALY estimation is unlikely to be biased if balanced trial allocation is achieved and subsequent collection of health-related quality of life data occurs at the earliest possible opportunity following commencement of treatment, followed by an adequate number of follow-up assessments. CONCLUSION: Trial-based cost-utility analyses within emergency and critical illness settings have applied different methods for QALY estimation, employing disparate assumptions about the health-related quality of life of patients at baseline. Where baseline measurement is not practical, measurement at the earliest opportunity following commencement of treatment should minimise bias in QALY estimation.
Authors: S Harvey; K Stevens; D Harrison; D Young; W Brampton; C McCabe; M Singer; K Rowan Journal: Health Technol Assess Date: 2006-08 Impact factor: 4.014
Authors: Steve Goodacre; Jon Nicholl; Simon Dixon; Elizabeth Cross; Karen Angelini; Jane Arnold; Sue Revill; Tom Locker; Simon J Capewell; Deborah Quinney; Stephen Campbell; Francis Morris Journal: BMJ Date: 2004-01-14
Authors: M J Rowland; T Veenith; C Scomparin; M H Wilson; P J Hutchinson; A G Kolias; R Lall; S Regan; J Mason; Pjd Andrews; D Horner; J Naisbitt; A Devrell; A Malins; P Dark; D F McAuley; G D Perkins Journal: J Intensive Care Soc Date: 2020-02-25
Authors: Jonathan R Benger; Kim Kirby; Sarah Black; Stephen J Brett; Madeleine Clout; Michelle J Lazaroo; Jerry P Nolan; Barnaby C Reeves; Maria Robinson; Lauren J Scott; Helena Smartt; Adrian South; Elizabeth A Stokes; Jodi Taylor; Matthew Thomas; Sarah Voss; Sarah Wordsworth; Chris A Rogers Journal: Health Technol Assess Date: 2022-04 Impact factor: 4.106
Authors: Iftekhar Khan; Mandy Maredza; Melina Dritsaki; Dipesh Mistry; Ranjit Lall; Sarah E Lamb; Keith Couper; Simon Gates; Gavin D Perkins; Stavros Petrou Journal: Pharmacoecon Open Date: 2020-12
Authors: Felix Achana; Stavros Petrou; Jason Madan; Kamran Khan; Chen Ji; Anower Hossain; Ranjit Lall; Anne-Marie Slowther; Charles D Deakin; Tom Quinn; Jerry P Nolan; Helen Pocock; Nigel Rees; Michael Smyth; Simon Gates; Dale Gardiner; Gavin D Perkins Journal: Crit Care Date: 2020-09-27 Impact factor: 9.097